2025.01,Empagliflozin,Markets and News,API,Empagliflozin,864070-44-0
Title: Comprehensive Overview of Empagliflozin: Market Trends, Patents, and Competitive Landscape.png)
Abstract:
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used in the management of type 2 diabetes and heart failure with reduced ejection fraction (HFrEF). This paper provides a detailed analysis of Empagliflozin, including its original research manufacturer, approval timeline, patent status, market dynamics, global and Chinese sales, market competition, and generic drug presence. It also explores the key active pharmaceutical ingredient (API) and any significant news developments in the last six months.
Keywords:
Empagliflozin, SGLT2 inhibitor, type 2 diabetes, heart failure, global sales, China market, generic drugs, API, patent status.
1. Introduction:
Empagliflozin, marketed under the brand name Jardiance, is an SGLT2 inhibitor used for the treatment of type 2 diabetes and heart failure. SGLT2 inhibitors work by inhibiting the sodium-glucose cotransporter 2 in the kidneys, which results in reduced blood glucose levels. This paper explores the journey of Empagliflozin from its discovery to its current position in the global market, including key market trends, sales data, patent details, and the competitive landscape.
2. Manufacturer and Research Development:
Empagliflozin was developed by the German pharmaceutical company Boehringer Ingelheim in collaboration with Eli Lilly and Company. Boehringer Ingelheim holds the primary patent for the compound, while Eli Lilly handles marketing and distribution in several regions. Empagliflozin was first approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of type 2 diabetes.
The drug’s primary mechanism involves blocking the SGLT2 receptor in the kidneys, preventing glucose reabsorption and promoting the excretion of glucose through urine. Its clinical benefits extend beyond blood sugar control, as it has shown efficacy in reducing cardiovascular events, a crucial aspect for type 2 diabetes patients with concurrent cardiovascular risks.
3. Marketing Approval and Timeline:
Empagliflozin was approved for the following indications:
The approval in China came in 2019, following its earlier approvals in the United States and Europe.
4. Patent Status of Core Compounds:
The patent for the core compound, Empagliflozin, was filed by Boehringer Ingelheim and is set to expire in 2025 in major markets, including the United States. The patent on the crystalline form of Empagliflozin, granted in several countries, is facing challenges as generics are expected to enter the market soon after expiration. However, Boehringer Ingelheim holds several patents related to the drug’s formulations, potentially delaying the generic competition for some time.
As of 2023, generic manufacturers are exploring alternative routes to market entry, leveraging patent challenges and the presence of specific drug formulations that may bypass certain patent protections.
5. Marketing Time in China:
Empagliflozin was officially approved in China in 2019 for the treatment of type 2 diabetes. The approval followed the success of similar SGLT2 inhibitors in the market, such as canagliflozin and dapagliflozin. Boehringer Ingelheim partnered with local distributors to ensure a smooth rollout of the drug. In China, Empagliflozin has quickly gained market share due to its robust clinical evidence supporting not just glycemic control but also its cardiovascular benefits.
6. Global Sales and Market Performance:
Empagliflozin has demonstrated significant commercial success globally. In 2022, global sales for Empagliflozin reached approximately $4 billion USD. The drug's popularity is largely due to its dual benefit for both diabetes management and heart failure, making it an attractive option for healthcare providers treating patients with coexisting conditions.
The sales were particularly robust in Europe and the United States, where the drug benefits from established reimbursement frameworks and widespread clinical use.
7. Sales in China:
In China, Empagliflozin has seen rapid uptake, with annual sales reaching approximately ¥1.5 billion in 2023. The increasing prevalence of diabetes and heart disease in China has driven demand for SGLT2 inhibitors, and Empagliflozin has positioned itself as a leading treatment option due to its efficacy and cardiovascular benefits.
8. Market Competition:
Empagliflozin faces competition from other SGLT2 inhibitors in the market, including:
These drugs are also used for type 2 diabetes and, in some cases, heart failure, leading to a competitive market for patients with multiple chronic conditions. Among these, Dapagliflozin and Canagliflozin have been the most significant competitors due to their broader indications, including chronic kidney disease.
9. Generic Drugs and Market Entry:
As Empagliflozin's patent expiration approaches, several pharmaceutical companies have begun developing generic versions of the drug. These include:
Generic Empagliflozin is expected to be launched shortly after the patent expiration in 2025, which will likely cause a decline in market prices and share for Boehringer Ingelheim’s branded product.
10. Key API and Related Technologies:
Active Pharmaceutical Ingredient
864070-44-0
Empagliflozin, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
http://foza.com.cn/product_en.html
11. News Developments in the Last Six Months:
12. Conclusion:
Empagliflozin has established itself as a leading treatment in the management of type 2 diabetes and heart failure, with strong market performance globally and in China. As the patent expires in 2025, the market will likely face significant changes with the entry of generic alternatives. Nevertheless, Empagliflozin’s unique cardiovascular benefits continue to drive its use, and it remains a key player in the global diabetes and cardiovascular drug markets.
References:
Image source | AI-generated illustration, not an actual product image
If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
